Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4463171 | 1.00 | BRD4 (0.42) | BRD4TP53SMN1; SMN2ALDH1A1CHRNB2 | |
| SCHEMBL17756080 | 1.00 | BRD4 (0.42) | BRD4TP53SMN1; SMN2ALDH1A1CHRNB2 | |
| Bicarbonate SCHEMBL7356898 | 0.96 | BRD4 (0.40) | BRD4TP53SMN1; SMN2ALDH1A1CHRNB2 | |
| SCHEMBL31267792 | 0.89 | SMN1; SMN2 (0.45) | BRD4TP53SMN1; SMN2ALDH1A1CHRNB2 | |
| SCHEMBL3879955 | 0.88 | TP53 (0.44) | BRD4TP53SMN1; SMN2ALDH1A1CHRNB2 | |
| SCHEMBL9957179 | 0.83 | — | — | |
| SCHEMBL9954696 | 0.81 | HRH3 (0.42) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL12401941 | 0.81 | HRH3 (0.42) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL1665962 | 0.79 | PDK1 (0.49) | SMN1; SMN2ALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL17014460 | 0.78 | BRD4 (0.47) | BRD4TP53SMN1; SMN2ALDH1A1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170290920-A1 | ANTI-CD22 ANTIBODIES AND IMMUNOCONJUGATES | MEDIMMUNE LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| US-20140030279-A1 | ANTI-CD22 ANTIBODIES AND IMMUNOCONJUGATES | SPIROGEN SARL (CH) | 2014-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290920-A1 | ANTI-CD22 ANTIBODIES AND IMMUNOCONJUGATES | CD22, CD2, CD2BP2 | BRD4 2527/4885TP53 2241/4885SMN1; SMN2 2478/4885 |
| US-20140030279-A1 | ANTI-CD22 ANTIBODIES AND IMMUNOCONJUGATES | CD22, CD2, CD2BP2 | BRD4 2527/4885TP53 2241/4885SMN1; SMN2 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.